Direct sequencing advantage Helicos offers direct RNA, DNA and cDNA sequencing without amplification, which reduces biases and simplifies workflows. This positioning presents a compelling value proposition for customers seeking high-fidelity, streamlined sequencing services and instrumentation utilization.

Single molecule tech The HeliScope system emphasizes true single-molecule sequencing and direct measurement, aligning with customers prioritizing accuracy at scale. Potential upsell opportunities include service contracts, consumables, and maintenance packages tied to the single-molecule platform.

Recent sequencing services Helicos has launched a sequencing services program, creating a channel to convert interest into revenue through access to their technology without full capital investment. This can be leveraged to cross-sell instrument access, training, and pilot projects.

Growth and funding signals With revenue in the tens of millions and substantial funding, the company may pursue strategic partnerships or collaborations with larger players or research institutes. This opens opportunities for co-development deals, licensing, or joint marketing arrangements.

Competitive positioning As an early entrant in single-molecule sequencing, Helicos competes with larger firms like Illumina, PacBio, and Oxford Nanopore. Sales opportunities exist in highlighting deployment flexibility, service-based access, and cost-effective experimentation for smaller labs or mid-tier biotech groups seeking alternatives to high-capital requirements.